Search

Your search keyword '"Ladaique P"' showing total 259 results
Start Over Author "Ladaique P"
259 results on '"Ladaique P"'

4. Melanopsin-Mediated Acute Light Responses Measured in Winter and in Summer: Seasonal Variations in Adults with and without Cataracts

Author

Mirjam Münch, Myriam Ladaique, Ségolène Roemer, Kattayoon Hashemi, and Aki Kawasaki

Subjects
pupil, cataract, melanopsin, melatonin, intrinsically photosensitive retinal ganglion cell, post-illumination pupil response, Neurology. Diseases of the nervous system, RC346-429
Abstract

Seasonal adaptation is a ubiquitous behavior seen in many species on both global hemispheres and is conveyed by changing photoperiods. In humans this seasonal adaptation is less apparent, in part because changes in daylength are masked by the use of electrical lighting at night. On the other hand, cataracts which reduce light transmission, may compound seasonal changes related to the reduced daylength of winter. To better understand the effects of different photoperiod lengths in healthy adults without and with cataracts, we tested their melanopsin-mediated light responses in summer vs. winter. Fifty-two participants (mean age 67.4 years; 30 with bilateral cataracts and 22 age-matched controls with clear lenses; pseudophakes) were tested twice, once in summer and once in winter. At each test session we assessed the electroretinogram and pupil responses during daytime and we determined melatonin suppression, subjective sleepiness and mood in response to light exposure in the evening. Circadian rest-activity cycles and sleep from activity recordings were also analyzed for both seasons. Both groups had similar visual function. There were no seasonal differences in the electroretinogram. For the pupil responses to bright blue light, the post-illumination pupil response (PIPR) was greater in winter than summer in pseudophakes, but not in cataract participants, whereas melatonin suppression to acute light exposure showed no differences between both groups and seasons. Overall, intra-daily variability of rest-activity was worse in winter but participants felt sleepier and reported worse mood at the laboratory in evening time in the summer. Those with cataracts had poorer sleep quality with lower sleep efficiency, and higher activity during sleep in winter than summer. In this study, the PIPR showed a seasonal variation in which a larger response was found during winter. This variation was only detected in participants with a clear intraocular lens. In the cataract group, visual function was not impaired yet these participants showed a lack of seasonal changes in the pupil response to blue light and poorer sleep in winter. These findings raise the question for tailored lighting conditions for cataract patients in order to counter potentially deleterious effects of living with chronically lower light exposure.

Published
2017
Full Text
View/download PDF

6. Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission

Author

Stoppa, A.-M., Faucher, C., Vey, N., Bouabdallah, R., Chabannon, C., Ladaique, P., Novakovitch, G., Aurran, T., Charbonnier, A., Coso, D., Sainty, D., Lafage, M., Costello, R., Blaise, D., Gastaut, J.-A., Maraninchi, D., Hiddemann, Wolfgang, editor, Haferlach, Torsten, editor, Unterhalt, Michael, editor, Büchner, Thomas, editor, and Ritter, Jörg, editor

Published
2003
Full Text
View/download PDF

32. When to do surgical resection for atypical breast lesions: Results of a prospective cohort of 518 lesions

Author

Cohen, Monique, Benhaim, Simon, Coudray, Aurélie Jalaguier, Chauvet, Marie Pierre, Ribierre, Sandra Giraud, Llorca, Frédérique Penault, Faure, Christelle, Opinel, Pierre, Bertrand, Pierre, Detroyer, Jeremy, Eisinger, François, Lambaudie, Eric, Dauplat, Marie Mélanie, Charafe Jauffret, Emmanuelle, Houvenaeghel, Gilles, Lecrivain, Françoise, Meynard, Paule, Gimbergues, Pierre, Chopin, Nicolas, Ladaique, Anaïs, Villard, Rim, Thomassin, Jeanne, Bannier, Marie, Paciencia, Maria, and Moretta, Jessica

Abstract

There is no consensual indication for surgical resection after diagnosis on per-cutaneous biopsy of borderline breast lesions (B3). We evaluate under-evaluation rate of per-cutaneous biopsy and predictive factors of under-evaluation. We analyze accuracy of reported decision-making tools.

Published
2020
Full Text
View/download PDF

33. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM.]

Author

Dettori, I, Ladaique, P, Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), and Dubois Frid, Caroline

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Blood Platelets, Academies and Institutes, Hospital Departments, Disease Management, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Platelet Transfusion, Allografts, Medical Oncology, Thrombocytopenia, Interinstitutional Relations, Isoantibodies, Hematologic Neoplasms, Blood Banks, Humans, Antigens, Human Platelet, Immunization, France, Spleen, Bone Marrow Transplantation
Abstract

International audience; The platelet refractoriness is a complication of transfusion treatments potentially dramatic in onco-haematology. Chemo-treatment of haematological malignancies or packs of allogeneic bone marrow transplants require iterative platelet transfusion requirements. The discovery of a platelet refractoriness along with its support should be the most reactive as possible but also adapted to the cause. In the case of allo-immunization, it may be expected. The purpose of this presentation is to recall the different etiologies and perform a feedback on the support transfusion platelet of onco-haematology adult patients at Institut Paoli-Calmettes (IPC) in partnership with the EFSAM.

Published
2014

38. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial

Author

Garban, Frédéric, Guyard, Audrey, Labussière, Helene, Bulabois, Claude-Eric, Marchand, Tony, Mounier, Christiane, Caillot, Denis, Bay, Jacques-Olivier, Coiteux, Valérie, Schmidt-Tanguy, Aline, Le Niger, Catherine, Robin, Christine, Ladaique, Patrick, Lapusan, Simona, Deconinck, Eric, Rolland, Carole, Foote, Alison M., François, Anne, Jacquot, Chantal, Tardivel, René, Tiberghien, Pierre, and Bosson, Jean-Luc

Abstract

IMPORTANCE: Pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity. OBJECTIVE: To compare the effectiveness of platelets in additive solution treated with amotosalen–UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and hematologic malignancies. DESIGN, SETTING, AND PARTICIPANTS: The Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) study was a randomized, noninferiority, 3-arm clinical trial performed from May 16, 2013, through January 21, 2016, at 13 French tertiary university hospitals. Clinical signs of bleeding were assessed daily until the end of aplasia, transfer to another department, need for a specific platelet product, or 30 days after enrollment. Consecutive adult patients with bone marrow aplasia, expected hospital stay of more than 10 days, and expected need of platelet transfusions were included. INTERVENTIONS: At least 1 transfusion of platelets in additive solution with amotosalen–UV-A treatment, in plasma, or in additive solution. MAIN OUTCOMES AND MEASURES: The proportion of patients with grade 2 or higher bleeding as defined by World Health Organization criteria. RESULTS: Among 790 evaluable patients (mean [SD] age, 55 [13.4] years; 458 men [58.0%]), the primary end point was observed in 126 receiving pathogen-reduced platelets in additive solution (47.9%; 95% CI, 41.9%-54.0%), 114 receiving platelets in plasma (43.5%; 95% CI, 37.5%-49.5%), and 120 receiving platelets in additive solution (45.3%; 95% CI, 39.3%-51.3%). With a per-protocol population with a prespecified margin of 12.5%, noninferiority was not achieved when pathogen-reduced platelets in additive solution were compared with platelets in plasma (4.4%; 95% CI, −4.1% to 12.9%) but was achieved when the pathogen-reduced platelets were compared with platelets in additive solution (2.6%; 95% CI, −5.9% to 11.1%). The proportion of patients with grade 3 or 4 bleeding was not different among treatment arms. CONCLUSIONS AND RELEVANCE: Although the hemostatic efficacy of pathogen-reduced platelets in thrombopenic patients with hematologic malignancies was noninferior to platelets in additive solution, such noninferiority was not achieved when comparing pathogen-reduced platelets with platelets in plasma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01789762

Published
2018
Full Text
View/download PDF

42. The Association Of Fludarabin, Oral Busulfan And Thymoglobulin Prior To Matched Related Allo-SCT Allows For High Long Term Outcome For Both Patients With Myeloid Or Lymphoid Malignancies: Long Term Analysis Of A Homogenous Cohort Of 100 Consecutive Patients

Author

Farnault, L., primary, Esterni, B., additional, Faucher, C., additional, Furst, S., additional, El Cheikh, J., additional, Ladaique, P., additional, Vey, N., additional, Bouabdallah, R., additional, Stoppa, A.M., additional, Lemarie, C., additional, Calmels, B., additional, Castagna, L., additional, Mohty, M., additional, Chabannon, C., additional, and Blaise, D., additional

Published
2010
Full Text
View/download PDF

43. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison

Author

Mohty, M, primary, de Lavallade, H, additional, El-Cheikh, J, additional, Ladaique, P, additional, Faucher, C, additional, Fürst, S, additional, Vey, N, additional, Coso, D, additional, Stoppa, A-M, additional, Gastaut, J-A, additional, Chabannon, C, additional, and Blaise, D, additional

Published
2008
Full Text
View/download PDF

44. COLLABORATIVE PROSPECTIVE-STUDY OF THE FRAGILE-X SYNDROME - ONE-YEAR PROGRESS REPORT

Author

Sherman, Sl, Barbi, G, Brondumnielsen, K, Brown, Wt, Carpenter, Nj, Chudley, Ae, Ferraz, Op, Ferreira, P, Gustavson, Kh, Halliday, J, Hockey, A, Howardpeebles, Pn, Jenkins, E, Kennerknecht, I, Kahkonen, M, Ladaique, P, Leisti, J, Maddalena, A, Mazurczak, T, Mattei, Jf, Mattina, Teresa, Mckinley, Mj, Murphy, P, Pellissier, Mc, Purvissmith, S, Robinson, H, Scapagnini, U, Schaap, T, Shapiro, Lr, Smits, Apt, Steinbach, P, Turner, G, Uchida, Ia, Vanoost, Ba, Voelckel, Ma, Weaver, Dd, Webb, T., and University of Groningen

Subjects
PARENTAL ORIGIN, FRAGILE-X SYNDROME, MALES, RECURRENCE RISKS, X-LINKED MENTAL RETARDATION, ISOLATED CASE
Abstract

A prospective study of the fragile X syndrome [fra(X)] was initiated one year ago to refine the estimates of recurrence risks based on the phenotype of the mother and the family history of the syndrome. The basic unit of data consists of the description of the conceptus of women known to carry the fra(X) gene or of mothers of an isolated case. To date, information on 261 women and their conceptuses was ascertained primarily through prenatal diagnosis; these data are summarized here. Although tests of significance were limited due to small sample sizes in subgroups, the following trends were observed: 1) the penetrance of fra(X) site expression was 80% in both male and female conceptuses suggesting that fra(X) site expression is equally penetrant early in development; 2) the sex ratio at the time of prenatal diagnosis did not differ from one, indicating that selection against fra(X) fetuses, if any, does not differ among sexes; 3) the recurrence risk among offspring of borderline/mildly retarded mothers was higher than that among offspring of intellectually normal mothers; 4) the recurrence risk in offspring did not differ based on the mother's fra(X) site expression; and 5) the recurrence risk in offspring of mothers with isolated cases was slightly less (34%) than that of obligate carrier mothers (41%) although this was not significant. The potential use of these prospective data on the fra(X) syndrome is emphasized.

Published
1992

45. 198: The use of recombinant human erythropoietin (rHuEpo) after reduced intensity conditioning (RIC) allogeneic hematopoietic peripheral blood stem cell transplantation (ASCT) reduces red blood cell (RBC) transfusion requirements

Author

Ivanov, V., primary, El Cheikh, J., additional, Faucher, C., additional, Furst, S., additional, Mohty, M., additional, Ladaique, P., additional, Lemarie, C., additional, Charbonnier, A., additional, Coso, D., additional, Schiano, J.M., additional, Viret, F., additional, and Blaise, D., additional

Published
2007
Full Text
View/download PDF

47. Stem Cell Transplantation in 281 Patients over 60 Years in Onco Hematologic Malignancies: A Single Center Experience.

Author

Stoppa, Anne-Marie, primary, Vey, N., additional, Faucher, C., additional, Bouabdallah, R., additional, Viret, F., additional, Chabannon, C., additional, Ladaique, P., additional, Coso, D., additional, Charbonnier, A., additional, Schiano, J.M., additional, Viens, P., additional, Gastaut, J.A., additional, Maraninchi, D., additional, and Blaise, D., additional

Published
2004
Full Text
View/download PDF

49. CR1 acute myeloid leukemia and HLA-identical allogeneic transplantation (ASCT) prepared with reduced intensity regimen (RIC): leukemia control requires adequate pre graft chemotherapy and post graft GVHD

Author

Faucher, C., primary, Boiron, J.M., additional, Mohty, M., additional, Bay, J.O., additional, Perreau, V., additional, Bilger, K., additional, Vey, N., additional, Stoppa, A.M., additional, Coso, D., additional, Ladaique, P., additional, Maraninchi, D., additional, and Blaise, D., additional

Published
2004
Full Text
View/download PDF

50. Early treatment of anemia in patients undergoing chemotherapy, with erythropoietin: what is to be expected from a simplified regimen. About the experience at the Institut Paoli Calmettes-Marseille

Author

Braud, A.-C., primary, Schiano, J.-M., additional, Madroszyk, A., additional, Ladaique, P., additional, Viens, P., additional, Maraninchi, D., additional, Viret, F., additional, Tarpin, C., additional, Gravis, G., additional, Damaj, G., additional, Camerlo, J., additional, Goncalves, A., additional, Bertucci, F., additional, Coso, D., additional, and Vitot, M., additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results